

Our Ref: Q1 17 42

3 July 2017

- *I am writing to you today to request information relating to the treatment of schizophrenia by long acting depot injections/treatments.*
- *Within your organisation how many patients are currently [within the past six months] being treated for schizophrenia (ICD code: F20)?*

Within the last six months, Somerset Partnership NHS Foundation has provided care and treatment to 203 patients with a diagnosis of schizophrenia. The criteria used to identify these patients are those with an open mental health referral within last 6 months and with an active diagnosis of F20.

- *Of these patients, how many are currently [within the past six months] being treated with the following long acting depot therapies for schizophrenia (ICD code: F20):*

<b>Name of long acting injection depot drug</b>	<b>Number of patients treated in last six months *</b>
Olanzapine pamoate (Zypadhera)	55
Risperidone LAI (Risperdal Consta)	16
Aripiprazole LAI (Abilify Maintena)	10
Paliperidone palmitate, monthly (Xeplion)	18 * *
Paliperidone palmitate, 3 monthly (Trevicta)	
Zuclopenthixol decanoate (Clopixol)	37
Pipothiazine palmitate (Piportil)	2
Fluphenazine decanoate (Modecate)	3
Haloperidol decanoate (Haldol Decanoate)	60
Flupentixol decanoate (Depixol)	37

*\* The number of patients in the table above will not add up to the number of patients treated as patients can be treated with multiple drugs.*

*\*\* The Trust is unable to provide separate figures for the monthly and three monthly provision of this medication as it does not hold it in a way in which it can be collated.*